Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Onalespib + Talazoparib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Onalespib||AT13387|AT-13387||HSP90 Inhibitor 35||Onalespib (AT13387) inhibits Hsp90, which may result in decreased tumor growth (PMID: 22181674, PMID: 22714264, PMID: 32246062).|
|Talazoparib||Talzenna||BMN673||PARP Inhibitor (Pan) 22||Talzenna (talazoparib) is an inhibitor of PARP1 and PARP2, which prevents the DNA repair of single strand DNA breaks, thus causing the accumulation of DNA strand breaks, genomic instability and apoptosis, and leads to lethality in homologous recombination repair deficient cells (PMID: 28242752). Talzenna (talazoparib) is FDA approved for use in patients with ERBB2 (HER2)-negative breast cancer harboring deleterious or suspected deleterious germline BRCA mutations (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02627430||Phase I||Onalespib + Talazoparib||Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer||Withdrawn||0|